Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis

D Ménaché(American Red Cross), Gilbert White(Thiel College), Amy D. Shapiro(American Red Cross), Fred Darr(American Red Cross), Arthur R. Thompson(Norwich Research Park), Robert R. Montgomery(Medical College of Wisconsin), Pradyumna D. Phatak(American Red Cross), Joan Cox Gill(American Red Cross), David L. Aronson(George Washington University), Jeanne M. Lusher(Science Factory), Craig M. Kessler(Georgetown University)
British Journal of Haematology
September 1, 1996
10.1046/j.1365-2141.1996.d01-1860.x
Cited by 57

Related Papers

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council
|Journal of Pain|2016|3.1k
PECAM-1 (CD31) Cloning and Relation to Adhesion Molecules of the Immunoglobulin Gene Superfamily
|Science|1990|954
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2003|809